Peanut Allergy – Pipeline Review, H2 2012

Published by: Global Markets Direct

Published: Aug. 31, 2012 - 44 Pages

Table of Contents

Introduction

Global Markets Direct Report Coverage

Peanut Allergy Overview

Therapeutics Development

An Overview of Pipeline Products for Peanut Allergy

Peanut Allergy Therapeutics under Development by Companies

Peanut Allergy Therapeutics under Investigation by Universities/Institutes

Mid Clinical Stage Products

Comparative Analysis

Early Clinical Stage Products

Comparative Analysis

Pre-Clinical Stage Products

Comparative Analysis

Peanut Allergy Therapeutics – Products under Development by Companies

Peanut Allergy Therapeutics – Products under Investigation by Universities/Institutes

Companies Involved in Peanut Allergy Therapeutics Development

Novartis AG

DBV Technologies

Circassia Holdings Ltd.

Immunomic Therapeutics, Inc.

Peanut Allergy – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Omalizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ViaSkin Peanut - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ViaSkin Peanut - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Trichuris Suis Ova - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ToleroMune Dog Allergy T Cell Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

QGE-031 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ARA-LAMP Vax - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peanut Allergy Therapeutics – Drug Profile Updates

Peanut Allergy Therapeutics - Dormant Products

Peanut Allergy – Product Development Milestones

Featured News & Press Releases

Aug 02, 2012: DBV Technologies Initiates VIPES Phase IIb Clinical Study For Treatment Of Peanut Allergy

Jun 18, 2012: DBV Technologies Presents Phase Ib Clinical Study Results Of VIASKIN In Peanut-Allergic Patients At EAACI Congress

Feb 28, 2012: DBV Technologies Receives FDA Fast Track Designation For Viaskin Peanut

May 17, 2011: DBV Demonstrates Ability Of VIASKIN To Administer Allergen

Sep 01, 2010: VIASKIN PEANUT Selected for U.S. Consortium of Food Allergy Research’s Peanut Allergy Desensitization Trial Funded by the NIH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products Under Development for Peanut Allergy, H2 2012

Products under Development for Peanut Allergy – Comparative Analysis, H2 2012

Number of Products under Development by Companies, H2 2012

Number of Products under Investigation by Universities/Institutes, H2 2012

Comparative Analysis by Mid Clinical Stage Development, H2 2012

Comparative Analysis by Early Clinical Stage Development, H2 2012

Comparative Analysis by Pre-Clinical Stage Development, H2 2012

Products under Development by Companies, H2 2012

Products under Investigation by Universities/Institutes, H2 2012

Novartis AG, H2 2012

DBV Technologies, H2 2012

Circassia Holdings Ltd., H2 2012

Immunomic Therapeutics, Inc., H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Peanut Allergy Therapeutics – Drug Profile Updates

Peanut Allergy Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Peanut Allergy, H2 2012

Products under Development for Peanut Allergy – Comparative Analysis, H2 2012

Products under Development by Companies, H2 2012

Products under Investigation by Universities/Institutes, H2 2012

Mid Clinical Stage Products, H2 2012

Early Clinical Stage Products, H2 2012

Pre-Clinical Stage Products, H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Route of Administration, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Molecule Type, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Abstract

• A snapshot of the global therapeutic scenario for Peanut Allergy.
• A review of the Peanut Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Peanut Allergy pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

• Identify and understand important and diverse types of therapeutics under development for Peanut Allergy.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Peanut Allergy therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.